Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Current strategies to target p53 in cancer.

Chen F, Wang W, El-Deiry WS.

Biochem Pharmacol. 2010 Sep 1;80(5):724-30. doi: 10.1016/j.bcp.2010.04.031. Epub 2010 May 5. Review.

PMID:
20450892
2.

The genetics of the p53 pathway, apoptosis and cancer therapy.

Vazquez A, Bond EE, Levine AJ, Bond GL.

Nat Rev Drug Discov. 2008 Dec;7(12):979-87. doi: 10.1038/nrd2656. Review.

PMID:
19043449
3.

Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells.

Yang B, Eshleman JR, Berger NA, Markowitz SD.

Clin Cancer Res. 1996 Oct;2(10):1649-57.

4.

p53: an overview of over two decades of study.

Cheah PL, Looi LM.

Malays J Pathol. 2001 Jun;23(1):9-16. Review.

PMID:
16329542
5.
6.

Apoptosis and growth arrest induced by platinum compounds in U2-OS cells reflect a specific DNA damage recognition associated with a different p53-mediated response.

Gatti L, Supino R, Perego P, Pavesi R, Caserini C, Carenini N, Righetti SC, Zuco V, Zunino F.

Cell Death Differ. 2002 Dec;9(12):1352-9.

7.

Activation of p53 by specific agents in potential cancer therapy.

Ho JW, Song JZ, Leung YK.

Curr Med Chem Anticancer Agents. 2005 Mar;5(2):131-5. Review.

PMID:
15777220
8.

Modulating the p53 pathway.

Dey A, Lane DP, Verma CS.

Semin Cancer Biol. 2010 Feb;20(1):3-9. doi: 10.1016/j.semcancer.2010.02.004. Epub 2010 Mar 1. Review.

PMID:
20193765
10.

Regulating the p53 system through ubiquitination.

Yang Y, Li CC, Weissman AM.

Oncogene. 2004 Mar 15;23(11):2096-106. Review.

PMID:
15021897
11.

Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression.

Li PX, Wong J, Ayed A, Ngo D, Brade AM, Arrowsmith C, Austin RC, Klamut HJ.

J Biol Chem. 2000 Jun 30;275(26):20127-35.

12.
14.

Improving cancer therapy through p53 management.

Haupt S, Haupt Y.

Cell Cycle. 2004 Jul;3(7):912-6. Epub 2004 Jul 2. Review.

PMID:
15254405
15.

Therapeutic targeting of p53 by small molecules.

Selivanova G.

Semin Cancer Biol. 2010 Feb;20(1):46-56. doi: 10.1016/j.semcancer.2010.02.006. Epub 2010 Mar 3. Review.

PMID:
20206268
16.

P53: an ubiquitous target of anticancer drugs.

Blagosklonny MV.

Int J Cancer. 2002 Mar 10;98(2):161-6. Review.

17.

p53 as a target for anti-cancer drug development.

Bouchet BP, Caron de Fromentel C, Puisieux A, Galmarini CM.

Crit Rev Oncol Hematol. 2006 Jun;58(3):190-207. Epub 2006 May 9. Review.

PMID:
16690321
18.

The discovery of nongenotoxic activators of p53: building on a cell-based high-throughput screen.

McCarthy AR, Hollick JJ, Westwood NJ.

Semin Cancer Biol. 2010 Feb;20(1):40-5. doi: 10.1016/j.semcancer.2010.02.007. Epub 2010 Mar 4. Review.

PMID:
20206696
19.

p53-targeted cancer pharmacotherapy: move towards small molecule compounds.

Kim SH, Dass CR.

J Pharm Pharmacol. 2011 May;63(5):603-10. doi: 10.1111/j.2042-7158.2010.01248.x. Epub 2011 Mar 31. Review.

PMID:
21492161
20.

p53 is balancing development, differentiation and de-differentiation to assure cancer prevention.

Molchadsky A, Rivlin N, Brosh R, Rotter V, Sarig R.

Carcinogenesis. 2010 Sep;31(9):1501-8. doi: 10.1093/carcin/bgq101. Epub 2010 May 26. Review.

PMID:
20504879

Supplemental Content

Support Center